Patents by Inventor Ling Mei
Ling Mei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220290235Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: January 28, 2022Publication date: September 15, 2022Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Patent number: 11294011Abstract: Methods, devices, apparatus and systems for magnetic resonance imaging with deep neural networks are provided. In one aspect, a method of magnetic resonance imaging method combines a deep neural network and an accelerated imaging manner. The method includes: scanning a subject with a first undersampling factor and a first sampling trajectory to obtain first imaging information, processing the first imaging information with the deep neural network to obtain second imaging information corresponding to a second undersampling factor that is smaller than the first undersampling factor, and reconstructing a magnetic resonance image of the subject from the second imaging information.Type: GrantFiled: January 7, 2020Date of Patent: April 5, 2022Assignee: Shanghai Neusoft Medical Technology Co., Ltd.Inventors: Feng Huang, Dong Han, Ling Mei
-
Patent number: 11268149Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: GrantFiled: November 13, 2019Date of Patent: March 8, 2022Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20200217914Abstract: Methods, devices, apparatus and systems for magnetic resonance imaging with deep neural networks are provided. In one aspect, a method of magnetic resonance imaging method combines a deep neural network and an accelerated imaging manner. The method includes: scanning a subject with a first undersampling factor and a first sampling trajectory to obtain first imaging information, processing the first imaging information with the deep neural network to obtain second imaging information corresponding to a second undersampling factor that is smaller than the first undersampling factor, and reconstructing a magnetic resonance image of the subject from the second imaging information.Type: ApplicationFiled: January 7, 2020Publication date: July 9, 2020Inventors: Feng HUANG, Dong HAN, Ling MEI
-
Publication number: 20200149110Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: November 13, 2019Publication date: May 14, 2020Inventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Patent number: 10544459Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: GrantFiled: May 29, 2015Date of Patent: January 28, 2020Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20180208988Abstract: The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Diseaese and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.Type: ApplicationFiled: March 14, 2018Publication date: July 26, 2018Inventors: Stephan R. Targan, Dermot P. McGovern, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20180143181Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H16, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.Type: ApplicationFiled: January 3, 2018Publication date: May 24, 2018Applicant: Industrial Technology Research InstituteInventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Chung Wang, Hsiang-Wen Tseng
-
Publication number: 20180142214Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug of the disclosure is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H28, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.Type: ApplicationFiled: January 3, 2018Publication date: May 24, 2018Applicant: Industrial Technology Research InstituteInventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Min Liu, Hsiang-Wen Tseng
-
Patent number: 9768132Abstract: A semiconductor structure includes a substrate, a bond pad over the substrate, and a passivation layer over the substrate and a peripheral region of the bond pad. The bond pad has a bonding region and the peripheral region surrounding the bonding region. The passivation layer has an opening defined therein, and the opening exposes the bonding region of the bond pad. A first vertical distance between an upper surface of the passivation layer and a surface of the bonding region ranges from 30% to 40% of a second vertical distance between a lower surface of the passivation layer and an upper surface of the peripheral region.Type: GrantFiled: March 14, 2012Date of Patent: September 19, 2017Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.Inventors: Ling Mei Lin, Chun Li Wu, Yung-Fa Lee
-
Patent number: 9627318Abstract: In some embodiments, an interconnect structure includes a base layer, a plurality of dielectric layers and a conductive structure. The base layer includes a conductive region. The plurality of dielectric layers are formed over the base layer. The plurality of dielectric layers includes a first dielectric layer and an etch stop layer under the first dielectric layer. The conductive structure includes a plug. The plug includes a central region and one or more footing regions. The footing regions are formed around the central region and formed at least partially in the first etch stop layer. A total width of the central region and one or more footing regions at a bottom level of the plurality of dielectric layers is at least about 5% more than a width of the central region at the bottom level of the plurality of dielectric layers.Type: GrantFiled: June 16, 2014Date of Patent: April 18, 2017Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.Inventors: Ling Mei Lin, Chun Li Wu, Yu-Pin Chang
-
Publication number: 20150364420Abstract: In some embodiments, an interconnect structure includes a base layer, a plurality of dielectric layers and a conductive structure. The base layer includes a conductive region. The plurality of dielectric layers are formed over the base layer. The plurality of dielectric layers includes a first dielectric layer and an etch stop layer under the first dielectric layer. The conductive structure includes a plug. The plug includes a central region and one or more footing regions. The footing regions are formed around the central region and formed at least partially in the first etch stop layer. A total width of the central region and one or more footing regions at a bottom level of the plurality of dielectric layers is at least about 5% more than a width of the central region at the bottom level of the plurality of dielectric layers.Type: ApplicationFiled: June 16, 2014Publication date: December 17, 2015Inventors: LING MEI LIN, CHUN LI WU, YU-PIN CHANG
-
Publication number: 20150337378Abstract: The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Disease and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.Type: ApplicationFiled: May 26, 2015Publication date: November 26, 2015Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Stephan R. Targan, Dermot P. McGovern, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20150259748Abstract: This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.Type: ApplicationFiled: May 29, 2015Publication date: September 17, 2015Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Stephan R. Targan, Marla C. Dubinsky, Carol J. Landers, Ling Mei, Jerome I. Rotter, Kent D. Taylor
-
Publication number: 20150159141Abstract: An isolated human liver tumor cell line is provided, which was named as ITRI-H28 and deposited in the Food Industry Research and Development Institute with the accession number BCRC960457 on Dec. 14, 2012. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H28 and adding an interest compound into the ITRI-H28 cell line to determine an effect on the ITRI-H28 cell line.Type: ApplicationFiled: October 9, 2014Publication date: June 11, 2015Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Min Liu, Hsiang-Wen Tseng
-
Publication number: 20150160195Abstract: An isolated human liver tumor cell line is provided and is named as ITRI-H16, and which was deposited in the Food Industry Research and Development Institute with the accession number BCRC960432 on Nov. 7, 2011. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H16 and treating an interest compound to the ITRI-H16 cell line to determine an effect of the interesting compound on the ITRI-H16 cell line.Type: ApplicationFiled: October 13, 2014Publication date: June 11, 2015Inventors: Mei-Wei Lin, Dian-Kun Li, Ling-Mei Wang, Ching-Huai Ko, Chin-Pen Lai, Chun-Chung Wang, Hsiang-Wen Tseng
-
Patent number: 8758756Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.Type: GrantFiled: September 12, 2012Date of Patent: June 24, 2014Assignee: Industrial Technology Research InstituteInventors: Hsiang-Ching Wang, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
-
Publication number: 20130241064Abstract: A semiconductor structure includes a substrate, a bond pad over the substrate, and a passivation layer over the substrate and a peripheral region of the bond pad. The bond pad has a bonding region and the peripheral region surrounding the bonding region. The passivation layer has an opening defined therein, and the opening exposes the bonding region of the bond pad. A first vertical distance between an upper surface of the passivation layer and a surface of the bonding region ranges from 30% to 40% of a second vertical distance between a lower surface of the passivation layer and an upper surface of the peripheral region.Type: ApplicationFiled: March 14, 2012Publication date: September 19, 2013Applicant: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.Inventors: Ling Mei LIN, Chun Li WU, Yung-Fa LEE
-
Publication number: 20130171174Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.Type: ApplicationFiled: September 12, 2012Publication date: July 4, 2013Inventors: Hsiang-Ching WANG, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
-
Patent number: D1024051Type: GrantFiled: August 10, 2021Date of Patent: April 23, 2024Assignee: Acer IncorporatedInventors: Hui-Jung Huang, Hong-Kuan Li, I-Lun Li, Ling-Mei Kuo, Kuan-Ju Chen, Fang-Ying Huang, Kai-Hung Huang, Szu-Wei Yang, Kai-Teng Cheng